Treatment Patterns and Comorbidities Associated with Multiple System Atrophy: A Comparative Study
Objective: To examine comorbidities and co-medications in patients with multiple system atrophy (MSA) compared to a matched-control in real-world setting Background: Currently MSA is managed…Syllable-based speech characteristics as potential biomarker for differential diagnosis of Parkinson’s disease, multiple system atrophy, and cerebellar ataxia
Objective: To analyze syllable-based speech characteristics in patients with Parkinson’s disease (PD), multiple system atrophy (MSA), and cerebellar ataxia (CA) to determine if there is…Familial Multiple System Atrophy-Mimics: Importance of Comprehensive Evaluation
Objective: We present two patients initially diagnosed as familial MSA until one of the patients was proven to be metachromatic leukodystrophy (MLD). Background: Multiple system…Clinical and neuroimaging factors associated with survival in Multiple System Atrophy
Objective: To assess clinical and neuroimaging factors associated with survival in a cohort of patients with a final clinical diagnosis of Multiple System Atrophy (MSA)…Increasing diagnostic accuracy of Multiple System Atrophy – A Videolibrary on clinical and imaging features
Objective: To provide short, high-quality videos and MRI images presenting typical MSA features to supplement new MDS-MSA criteria1. Background: The MDS criteria for the diagnosis…Intraepidermal Nerve Fiber Density at Baseline Associates with One-year Clinical Disease Progression in Multiple System Atrophy
Objective: In a longitudinal manner explore possible diagnostic and prognostic properties of determining intraepidermal nerve fiber density (IENFD), by means of skin punch biopsy, in…Development and Validation of a Clinical Scale for Distinguishing Multiple System Atrophy from 4-Repeat Tauopathies
Objective: We aimed to develop a clinical scale that distinguishes between Multiple System Atrophy (MSA) and 4-repeat tauopathies (4RT: CBD, PSP) using a standardized neurological…Role of the Alpha-synuclein Seed Amplification Assay in Parkinson’s Disease Clinical Trials: A Case Report of Multiple System Atrophy Misdiagnosed as Parkinson’s Disease
Objective: Report a patient with Multiple System Atrophy (MSA) misdiagnosed as Parkinson’s disease (PD) and enrolled in a clinical trial for PD treatment with Mesenchymal…24-Hour Ambulatory Blood Pressure Monitoring and Dipping Patterns in Parkinson’s Disease and Multiple System Atrophy
Objective: To depict 24-hour blood pressure profile, especially dipping patterns, in individuals diagnosed with Parkinson’s Disease (PD) and Multiple System Atrophy (MSA). Background: Both PD…Catalan MSA Registry (CMSAR): Applying new Clinical Criteria and Biomarkers for Increasing Diagnostic Accuracy, is New Better?
Objective: To reassess the CMSAR and determine if new criteria and new biomarkers can enhance diagnostic accuracy. Background: The CMSAR, conducted between 2015 and 2019,…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 23
- Next Page »